Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
12/27/2025
Telix Advances Regulatory Efforts with Positive China Phase 3 Data
12/27/2025
CDE Seeks Comments on Chinese Translation of ICH M8 eCTD Guidelines
12/27/2025
NMPA Announces Adoption of ICH E6(R3) Guidelines for Clinical Trial Qu...
12/27/2025
Hemacell Completes Series B1 Financing to Advance Platelet Regeneratio...
12/27/2025
Chengdu Maxvax Biotech Completes D+ Financing Round
12/27/2025
China Approves Novo Nordisk's Sogroya for Pediatric Growth Hormone Def...
12/27/2025
LyncBio Therapeutics Completes Strategic Pre-A Financing Round
12/27/2025
Zai Lab's COBENFY Approve in China for Schizophrenia
12/27/2025
Frontera's HKSE IPO Application Accepted
12/27/2025
GRIT's Next-Generation Gene-Edited TIL GT307 Receives FDA IND Approval
12/27/2025
Guangzhou Novaken Pharm Files for HKSE Main Board Listing
12/27/2025
NMPA Approves Amgen/UCB's Evenity for Postmenopausal Osteoporosis
12/27/2025
Novo Nordisk's Wegovy Approved in China for Cardiovascular Risk Reduct...
12/27/2025
China Approves GSK's Nucala for Maintenance Treatment of Eosinophilic ...
12/27/2025
Coherent Licenses CBP-1018 to MultiValent Biotherapies in Major Global...
12/23/2025
Aurobindo Pharma to Increase Stake in Chinese JV Luoxin Aurovitas
12/23/2025
CSPC Announces China Approval for Daratumumab Injection
12/23/2025
Grand Secures China Rights to World's First Adrenaline Nasal Spray fr...
12/23/2025
Qilu Launches Phase 1 Trial of FIC CD3/CD20/CD79b Triple Antibody QLS2...
12/23/2025
Ipsen Expands Oncology Pipeline with Global Licensing of Simcere Zaimi...
12/23/2025
T-MAXIMUM Secures FDA Approval to Advance Off-the-Shelf CAR-T Therapy
12/23/2025
PepBio Raises Series A Financing to Advance AI-Driven Peptide Drug Pip...
12/23/2025
China Approves First Global CSF-1R Inhibitor Pimicotinib for Rare Join...
12/22/2025
NMPA Announces Revision of Montelukast Product Labels to Strengthen Dr...
12/22/2025
Windward Bio Licenses Long-Acting TSLP/IL-13 Bispecific WIN027 from Qy...
12/22/2025
Zelgen Files for Hong Kong IPO, Showcasing Commercial Portfolio and Mu...
12/22/2025
AstraZeneca Strengthens KRAS Oncology Strategy with Pan-KRAS Deal from...
12/22/2025
Alphamab's IND for PD-L1/VEGFR2 Bispecific ADC JSKN027 Accepted in Chi...
12/22/2025
Rezubio Raises $20M Series A to Advance Membrane-Anchored Therapeutics...
12/22/2025
Epigenic Wins FDA IND Clearance for Novel Epigenetic Therapy Targeting...
Page:
1
/
59
Total number of articles:
1742
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit